Pfizer Inc. is in talks to buy Global Blood Therapeutics Inc., a maker of a recently approved drug for sickle cell disease, for about $5 billion.
Pfizer Inc. is in talks to buy Global Blood Therapeutics Inc., a maker of a recently approved drug for sickle cell disease, for about $5 billion.